237 related articles for article (PubMed ID: 21692070)
21. Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro.
Jarad M; Kuczynski EA; Morrison J; Viloria-Petit AM; Coomber BL
BMC Cell Biol; 2017 Jan; 18(1):10. PubMed ID: 28114883
[TBL] [Abstract][Full Text] [Related]
22. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
[TBL] [Abstract][Full Text] [Related]
23. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
[TBL] [Abstract][Full Text] [Related]
24. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1.
Bellone G; Silvestri S; Artusio E; Tibaudi D; Turletti A; Geuna M; Giachino C; Valente G; Emanuelli G; Rodeck U
J Cell Physiol; 1997 Jul; 172(1):1-11. PubMed ID: 9207920
[TBL] [Abstract][Full Text] [Related]
25. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
[TBL] [Abstract][Full Text] [Related]
26. Serum factors potentiate hypoxia-induced hepatotoxicity in vitro through increasing transforming growth factor-beta1 activation and release.
Kao YH; Jawan B; Goto S; Pan MC; Lin YC; Sun CK; Hsu LW; Tai MH; Cheng YF; Nakano T; Wang CS; Huang CJ; Chen CL
Cytokine; 2009 Jul; 47(1):11-22. PubMed ID: 19457680
[TBL] [Abstract][Full Text] [Related]
27. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
Chen A; Davis BH; Sitrin MD; Brasitus TA; Bissonnette M
Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G864-74. PubMed ID: 12223346
[TBL] [Abstract][Full Text] [Related]
30. [Altered expression of vascular endothelial growth factor and its receptors in transdifferentiated human proximal tubular epithelial cells induced by transforming growth factor beta1].
Zhou QG; Zheng FL; Wen YB; Tan XY; Duan L; Li Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):325-31. PubMed ID: 16038269
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Kim JY; Bae BN; Kwon JE; Kim HJ; Park K
APMIS; 2011 Jul; 119(7):449-59. PubMed ID: 21635552
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling.
Pen A; Moreno MJ; Durocher Y; Deb-Rinker P; Stanimirovic DB
Oncogene; 2008 Nov; 27(54):6834-44. PubMed ID: 18711401
[TBL] [Abstract][Full Text] [Related]
33. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Zhou R; Xiong B; Song H; Liu S; Wang X
Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727
[TBL] [Abstract][Full Text] [Related]
34. Expression of transforming growth factor-beta1 and hypoxia-inducible factor-1alpha in an experimental model of kidney transplantation.
Lario S; Mendes D; Bescós M; Iñigo P; Campos B; Alvarez R; Alcaraz A; Rivera-Fillat F; Campistol JM
Transplantation; 2003 May; 75(10):1647-54. PubMed ID: 12777850
[TBL] [Abstract][Full Text] [Related]
35. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.
Xu H; Becker CM; Lui WT; Chu CY; Davis TN; Kung AL; Birsner AE; D'Amato RJ; Wai Man GC; Wang CC
Fertil Steril; 2011 Oct; 96(4):1021-8. PubMed ID: 21821246
[TBL] [Abstract][Full Text] [Related]
36. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
37. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis.
Weeks BH; He W; Olson KL; Wang XJ
Cancer Res; 2001 Oct; 61(20):7435-43. PubMed ID: 11606377
[TBL] [Abstract][Full Text] [Related]
38. Induction of chemokine receptor CXCR4 expression by transforming growth factor-β1 in human basal cell carcinoma cells.
Chu CY; Sheen YS; Cha ST; Hu YF; Tan CT; Chiu HC; Chang CC; Chen MW; Kuo ML; Jee SH
J Dermatol Sci; 2013 Nov; 72(2):123-33. PubMed ID: 23856244
[TBL] [Abstract][Full Text] [Related]
39. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
[TBL] [Abstract][Full Text] [Related]
40. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
